- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
March 4, 2021Robins Kaplan Files Class Action Against Martin Shkreli and His Former Companies on Behalf of Blue Cross and Blue Shield of Minnesota
-
March 1, 2021Amy Churan Named an Insurance Trailblazer by National Law Journal
-
March 1, 2021Firm, Partner Recognized by Managing IP
-
March, 9, 2021The New Frontier of Software License Disputes
-
March 9, 2021Health Care Antitrust under President Biden
-
March 11, June 10, and October 7, 2021New York Women in Antitrust Group Spotlight Series
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
March 5, 2021Financial Daily Dose 3.5.2021 | Top Story: Powell Tries to Sooth Jumpy Markets Fearing Weak Jobs Report
-
March 4, 2021Financial Daily Dose 3.4.2021 | Top Story: Google Shakes Up Digital Ad Industry by Phasing Out Web Tracking
-
March 3, 2021Financial Daily Dose 3.3.2021 | Top Story: Rare Merck-J&J Partnership to Boost U.S. Vaccine Production
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Miles A. Finn, Ph.D.
Miles A. Finn, Ph.D.
Counsel
Experience
- Practices in the Patent Office Trial Group. Has participated in over 15 IPRs and CBMs, representing both Petitioners and Patent Owners.
- Has extensive litigation and licensing experience in electrical engineering matters, including mobile telephony, RF connectors, and semiconductor chip design and fabrication.
- Brings 15 years of practical engineering experience and 5 years of patent litigation support to his position as an attorney in the Firm's patent litigation department. After earning a Bachelor's degree in physics (Franklin and Marshal College, magna cum laude) and a Ph.D. degree in physics (University of Minnesota) he worked as a scientist and an engineer in the medical device and software fields.
- Has invented a line of surgical "seeing instruments," resulting in 5 patents and two license agreements. Was awarded three National Institutes of Health research grants, totaling $575,000.
- In 2003, passed the U.S. Patent and Trademark Office patent bar exam, and joined Robins Kaplan LLP as a Science Advisor.
Patents
- 4,948,257 Laser Optical measuring device and method for stabilizing fringe pattern spacing
- 5,512,034 Surgical instrument including viewing optics and a ball probe
- 5,667,472 Surgical instrument and method for use with a viewing system
- 5,667,473 Surgical instrument and method for use with a viewing system
- 5,667,478 Surgical instrument with stick-on-fiber-optic viewing system and method of using
- 5,735,792 Surgical instrument including viewing optics and an atraumatic probe
- Science Advisor with Robins Kaplan LLP for five years providing patent litigation support before becoming an associate.
- 15 years of experience in medical and high-technology industries, with broad experience in many functional areas, including intellectual property, engineering, regulatory, sales and marketing. Medical fields with experience include neurosurgery, pain management, orthopedics, vascular, and urology.
PCT International. Inc. v. Amphenol Corp., IPR 2013-00229 (filed April 2, 2013) (cancelling all challenged claims of U.S. Patent No. 7,544,094 (“Connector assembly with gripping sleeve”), a patent purportedly covering our client’s F-connectors.
Purdue Pharmaceutical Products L.P. v. Novel Laboratories, Inc: Represented Novel Laboratories, Inc., a pharmaceutical company seeking to market a generic version of Intermezzo®. Intermezzo® is a sublingual formulation of zolpidem indicated for middle-of-the-night insomnia. Following a 10-day bench trial, the judge found in favor of our client, ruling the asserted claims of all three patents invalid for obviousness. The Federal Circuit confirmed the invalidity findings in a summary affirmance.
Prior- art searcher for In re Certain Flash Memory Controllers, Drives, Memory Cards and Media Players and Products Containing Same where the ITC determined that claim 8 of U.S. Patent Number 7,137,011 was invalid for obviousness. (As a Science Advisor at Robins Kaplan LLP)
- Named a “New York Rising Star,” Super Lawyers (2016-2020)
- Phi Beta Kappa
Bar Admissions
- Minnesota
- U.S. Court of Appeals, Federal Circuit
- U.S. Disrict Court, Southern District of New York
- New York
- U.S. Patent and Trademark Office
- Maximize the Success of Patent Licensing and Enforcement
The Future of IP and Technology Law Forum, Boston, Massachusetts (May 9, 2017) - Neuroscope '95 (Moderator)
A lecture series on Neurondoscopy, AANS Annual Meeting, Minneapolis, Minnesota (November 2, 1995)
RESOURCES
Links to full publications and news releases.
PUBLICATIONS
March 2018
Winter 2017
ANDA Approvals
GENERICally Speaking Winter 2017
Winter 2017
ANDA Litigation Settlements
GENERICally Speaking Winter 2017
NEWS
September 13, 2018
September 22, 2017
September 21, 2016
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.